Induced pluripotent stem cells (iPSCs) were originally generated from mouse and human fibroblasts by retroviral introduction of Oct3/4, Sox2, c-Myc, and Klf4. iPSCs are similar to embryonic stem cells (ESCs) in morphology, proliferation, gene expression and pluripotency. Compared to ESCs, iPSCs have less ethical controversy and can be generated from various genetically identified individuals including disease patients or those having specific human leukocyte antigen (HLA) types. Patient-specific iPSCs provide unprecedented opportunities in disease research, drug screening, and toxicology. A stock of iPSCs constructed from HLA-homozygous donors would provide significant resources for stem cell therapy. Each induction experiment can result in up to 100 or more independent iPSC clones. These clones may vary qualitatively, considering responses to in vitro directed differentiation protocols and their propensity to produce tumors. In fact, we have shown that the origins of mouse iPSCs have profound effects on tumorigenicity. It is therefore essential to determine the best induction protocols, and the best methods to evaluate these clones for future clinical applications. From this point of view, the need for genetic and epigenetic analyses becomes more significant. It is also important to note that iPSC within a clone can be heterogeneous, despite their common derivation from a single progenitor cell. This is likely because the process requires multiple cell division and cannot be completed by the four exogenous factors alone. Additional endogenous factors are required to achieve full reprogramming. Better understanding of the reprogramming mechanism will facilitate more uniform and complete reprogramming during iPSC generation. EDUCATION: 1981EDUCATION: -1987 MD, Kobe University, School of Medicine, Kobe, Japan 1989-1993 PhD, Division of Medicine, Osaka City University Graduate School, Osaka, Japan 
